In conclusion, our study demonstrates for the first time that CELSR2 promotes human glioma growth via the WNT3A/β-catenin pathway and administration of MNPs-loaded CELSR2-siRNA is a promising therapeutic strategy for gliomas. Here, WNT3A is linked to central nervous system cancer.